Education

Eastern Washington University, BS-Nursing, Cheney, WA,1980 – 1984

University of Pennsylvania, Post Baccalaureate Pre-Med , Philadelphia, PA,1990 -1991

Medical College of Pennsylvania, Doctor of Medicine, Philadelphia, PA 1991 – 1995

Post-Graduate Education

University of Iowa Hospitals and Clinics, Iowa City, IA, Resident, Obstetrics and Gynecology, 1995-1999

University of Iowa, Iowa City, IA, K-30 Fellow, Clinical Investigation Certificate 2002 - 2004

University of Iowa Carver College of Medicine, Iowa City, IA, Master of Science - Epidemiology, 2002-2004

Certification

American Board of Obstetrics and Gynecology, recertified annually

Licensure

Iowa

Professional and Academic Positions

• Staff, Obstetrician/Gynecologist Group Health Cooperative, Olympia, WA, 1999-2002
• Associate, Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, IA, 2002-2005
• Assistant Professor, Department of Obstetrics and Gynecology University of Iowa Hospitals and Clinics, Iowa City, IA, 2005 -2010
• Clinical Associate Professor, Department of Obstetrics and Gynecology University of Iowa Hospitals and Clinics, Iowa City, IA, 2010-
• Clinical Clerkship Director, Obstetrics and Gynecology, University of Iowa Carver College of Medicine, Iowa City, IA, 2010–
• Director, Vulvar Vaginal Disease Clinic
• Director, Colposcopy Clinics

Areas of Research Interest

• Lower Genital Tract Diseases
• Vulvovaginal Diseases
• Vulvodynia

Completed Projects

Federal/NIH/CDC

Primary-Investigator - K23 HD45769-01: Mentored Patient-Oriented Research Career Development Award. Vulvar Disease and Bladder and Bowel Symptoms. National Institute of Child Health and Development.

Institutional

General Clinical Research Center Pilot Grant. Vulvar Pain: Treatment trial using gabapentin.

Clinical Trials

1547-851B-62 A Randomized, USA and Canada, Multicenter, Placebo-Controlled Phase II Study of Multiple Dosing Regimens of Intravaginally Administered 851B Gel for the Treatment of Cervical High Risk HPV Infection.

V503-001. A Randomized, International, Double-Blinded, Controlled with Gardasil, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Second Generation Human Papillomavirus L1 Virus-Like Particle Vaccine administered to 16-26 year old women.

A randomized, worldwide, placebo-controlled, double-blind, study to investigate the safety, immunogenicity and efficacy on the incidence of HPV 16/18 related CIN 2/3 or worse of the Quadrivalent HPV (6,11,16,18) L1 Virus Like Particle Vaccine in 16-23 year old Women – the Future II Study.

A Phase III, double blind, randomized, controlled, multicenter study to evaluate the efficacy of HPV 16/18 VLP/ASO4 Vaccine.

A double-blind, randomized, controlled Phase III study to assess the prophylactic efficacy and safety of gDAlum/MPL vaccine in the prevention of genital herpes disease in young women who are HSV-1 and -2 seronegative.

HPV-015: A phase III, double-blind, randomized, controlled study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 month) in healthy adult female subjects aged 26 years and above.

Co-Investigator - 1485-R851: Phase I, Rising Multiple-Dose Safety, Pharmacokinetic, and Pharmacodynamic Study of R-851 Gel Delivered Intravaginally to Female Subjects with Cervical Dysplasia. 3M Pharmaceuticals. 2003-2004.

Co-Investigator - A double-blind, randomized, controlled Phase III study to assess the prophylactic efficacy and safety of gDAlum/MPL vaccine in the prevention of genital herpes disease in young women who are HSV-1 and -2 seronegative. National Institute of Allergy and Infectious Diseases/GlaxoSmithKline. 2003-2004.